Adrian Laughlin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adrian Laughlin has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Patty Chondros
Department of General Practice, University of Melbourne, Melbourne, VIC, Australia
5 shared publications - Jo-Anne Manski-Nankervis
Department of General Practice and Primary Care, The University of Melbourne, Melbourne, Victoria, Australia
4 shared publications - Jon Emery
Nanyang Technological University 5 Singapore
4 shared publications - Barbara Hunter
Department of General Practice and Primary Care, University of Melbourne, Melbourne, Australia
3 shared publications - Craig Nelson
Western Health Chronic Disease Alliance, Western Health Melbourne, Melbourne, Australia
3 shared publications - Douglas Boyle
Department of General Practice and Primary Care, University of Melbourne, Melbourne, Australia
3 shared publications
Latest Publications
- Open Access
- 4 June 2026
- Published by Springer Nature in Pilot and Feasibility Studies
- Vol. 12 (1)
The Richards Trauma Process: a before-after single-arm feasibility trial of a novel psychotherapy
The Richards Trauma Process (TRTP) is a novel, very brief transdiagnostic psychotherapy that uses innovative methods to work with parts of the self to reprocess traumatic memories without using exposure techniques. Our objectives were to explore the feasibility of studying this therapy in a community setting, to document the safety and acceptability of TRTP, and to gather preliminary indications of outcomes in adults presenting with elevated levels of psychological distress. This was a before-after single-arm trial of TRTP in consecutive new adult clients presenting to a psychotherapist in Australia. Inclusion criteria were at least mildly elevated levels of depression, anxiety, stress or trauma symptoms; no previous diagnosis of psychosis, Bipolar Disorder or Personality Disorder; and ability to maintain sobriety during the therapy. Feasibility was assessed against 15 criteria relating to 5 broad objectives, evaluating: (1) recruitment and retention capability, (2) data collection procedures, (3) resourcing, (4) acceptability and safety of TRTP, and (5) change in scores. Regarding objective 5, we estimated the mean change in scores on the Depression, Anxiety and Stress Scales (DASS21) and PTSD Checklist for DSM-5 (PCL-5) between follow-up and baseline; and to check for harms (objective 4) we used descriptive statistics to look for clinically meaningful deterioration in individual scores or participants. Of 40 new clients, 23 (58%; 95% Confidence Interval (CI) 41% to 73%) were eligible, consented to the study and commenced TRTP. Of these, 20 (87%; 95% CI 65% to 97%) completed TRTP (averaging six hours of therapy) and follow-up 1-month post-therapy. Eleven of 15 feasibility criteria were met. Unmet criteria could be addressed in a future efficacy trial by modifications to study procedures. All mean scores changed in the desired direction, with no individual scores or participants demonstrating clinically meaningful deterioration. This is the first study that supports the feasibility of a larger trial of TRTP in a community setting. We demonstrated that recruitment and retention of participants, and data collection, were feasible, and that the intervention was acceptable, safe, and worthy of further study. Learnings for a future trial were identified. Retrospectively registered with The Australian and New Zealand Clinical Trials Registry (ACTRN12625001423404).
- 4 June 2026
- Published by Springer Nature in Pilot and Feasibility Studies
- Vol. 12 (1)
Open AccessThe Richards Trauma Process: a before-after single-arm feasibility trial of a novel psychotherapy
The Richards Trauma Process (TRTP) is a novel, very brief transdiagnostic psychotherapy that uses innovative methods to work with parts of the self to reprocess traumatic memories without using exposure techniques. Our objectives were to explore the feasibility of studying this therapy in a community setting, to document the safety and acceptability of TRTP, and to gather preliminary indications of outcomes in adults presenting with elevated levels of psychological distress. This was a before-after single-arm trial of TRTP in consecutive new adult clients presenting to a psychotherapist in Australia. Inclusion criteria were at least mildly elevated levels of depression, anxiety, stress or trauma symptoms; no previous diagnosis of psychosis, Bipolar Disorder or Personality Disorder; and ability to maintain sobriety during the therapy. Feasibility was assessed against 15 criteria relating to 5 broad objectives, evaluating: (1) recruitment and retention capability, (2) data collection procedures, (3) resourcing, (4) acceptability and safety of TRTP, and (5) change in scores. Regarding objective 5, we estimated the mean change in scores on the Depression, Anxiety and Stress Scales (DASS21) and PTSD Checklist for DSM-5 (PCL-5) between follow-up and baseline; and to check for harms (objective 4) we used descriptive statistics to look for clinically meaningful deterioration in individual scores or participants. Of 40 new clients, 23 (58%; 95% Confidence Interval (CI) 41% to 73%) were eligible, consented to the study and commenced TRTP. Of these, 20 (87%; 95% CI 65% to 97%) completed TRTP (averaging six hours of therapy) and follow-up 1-month post-therapy. Eleven of 15 feasibility criteria were met. Unmet criteria could be addressed in a future efficacy trial by modifications to study procedures. All mean scores changed in the desired direction, with no individual scores or participants demonstrating clinically meaningful deterioration. This is the first study that supports the feasibility of a larger trial of TRTP in a community setting. We demonstrated that recruitment and retention of participants, and data collection, were feasible, and that the intervention was acceptable, safe, and worthy of further study. Learnings for a future trial were identified. Retrospectively registered with The Australian and New Zealand Clinical Trials Registry (ACTRN12625001423404).
- Open Access
- 1 May 2026
- Published by Elsevier in SSRN Electronic Journal
The SCRIPT Trial: A Randomised Controlled Trial of a Polygenic Risk Score to Tailor Colorectal Cancer Screening in Australian General Practice
Background: Polygenic risk scores (PRS) can predict an individual’s risk of colorectal cancer (CRC) enabling tailoring of screening. The SCRIPT trial tested a complex intervention, including a PRS, in general practice to increase risk-appropriate CRC screening completion.Methods: This was a stratified, individually randomised controlled trial in eight general practices in Victoria, Australia. Patients aged 45-70 were consecutively approached for participation. For those over 50, those due CRC screening were eligible. The SCRIPT intervention comprised a CRC PRS, risk-tailored screening recommendations, and a risk report provided in a consultation and sent to participants’ GP. Control consultations included a discussion and brochure focused on lifestyle CRC risk factors.The primary outcome was the proportion completing risk-appropriate CRC screening by 12 months. In the SCRIPT arm, risk-appropriate screening was defined using PRS- and family history-derived CRC risk; in the control arm, it was defined using family history criteria. National screening guidelines, timing, type and results of previous screening were considered in both arms. Outcome assessors were blind to allocation (no other blinding was possible).Findings: Between 19/04/2021 and 23/08/2022, 276 participants (66% of those eligible) were randomised (138 control, 138 intervention). Three were withdrawn (one in each arm deemed ineligible, one control participant withdrew all data). Intention-to-treat analysis included 137 intervention and 136 control participants. In the SCRIPT arm, 62.8% (n=86) completed risk-appropriate CRC screening within 12 months, compared to 47.8% (n=65) of control participants – an increase of 14.9% (95% confidence interval: 3.5%-26.4%, p=0.012).Interpretation: This is the first trial to show that personalised genomic cancer risk information can be effectively incorporated into a primary care intervention to increase appropriate cancer screening completion. This is a key finding for effective implementation of risk-stratified population cancer screening – ensuring the correct screening is recommended, while optimising participation.
- 1 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessThe SCRIPT Trial: A Randomised Controlled Trial of a Polygenic Risk Score to Tailor Colorectal Cancer Screening in Australian General Practice
Background: Polygenic risk scores (PRS) can predict an individual’s risk of colorectal cancer (CRC) enabling tailoring of screening. The SCRIPT trial tested a complex intervention, including a PRS, in general practice to increase risk-appropriate CRC screening completion.Methods: This was a stratified, individually randomised controlled trial in eight general practices in Victoria, Australia. Patients aged 45-70 were consecutively approached for participation. For those over 50, those due CRC screening were eligible. The SCRIPT intervention comprised a CRC PRS, risk-tailored screening recommendations, and a risk report provided in a consultation and sent to participants’ GP. Control consultations included a discussion and brochure focused on lifestyle CRC risk factors.The primary outcome was the proportion completing risk-appropriate CRC screening by 12 months. In the SCRIPT arm, risk-appropriate screening was defined using PRS- and family history-derived CRC risk; in the control arm, it was defined using family history criteria. National screening guidelines, timing, type and results of previous screening were considered in both arms. Outcome assessors were blind to allocation (no other blinding was possible).Findings: Between 19/04/2021 and 23/08/2022, 276 participants (66% of those eligible) were randomised (138 control, 138 intervention). Three were withdrawn (one in each arm deemed ineligible, one control participant withdrew all data). Intention-to-treat analysis included 137 intervention and 136 control participants. In the SCRIPT arm, 62.8% (n=86) completed risk-appropriate CRC screening within 12 months, compared to 47.8% (n=65) of control participants – an increase of 14.9% (95% confidence interval: 3.5%-26.4%, p=0.012).Interpretation: This is the first trial to show that personalised genomic cancer risk information can be effectively incorporated into a primary care intervention to increase appropriate cancer screening completion. This is a key finding for effective implementation of risk-stratified population cancer screening – ensuring the correct screening is recommended, while optimising participation.
- Open Access
- 14 July 2025
- Published by CSIRO Publishing in Australian Journal of Primary Health
- Vol. 31 (4)
Adolescent health presentations to Victorian general practice: a descriptive study using electronic medical records
Background: Although most young Australians visit their general practitioner at least once a year, discrepancies remain between healthcare need and healthcare support in this group. A detailed contemporary understanding of youth presentations to general practice is needed, given that the last comprehensive investigation into Australian adolescent encounters with primary care is now over two decades old. The aim of this study is to describe rates of presentation and reasons for visit among young people in Victorian primary care using data extracted from electronic medical records. Methods: A retrospective descriptive study of de-identified electronic medical records data from >22,000 adolescents aged 10–24 years who presented to Victorian general practice in 2019 was undertaken. Results: The overall mean attendance rate of young people was 2.89 visits/patient per year, with rates highest amongst older patients, females and those in regional localities. Young people presented most frequently for physical (biomedical) concerns (such as respiratory, skin and general physical complaints), and psychological (mental health) reasons for visit. Conclusions: The study addresses a significant gap in our understanding of the role of general practice for young Australians. Although physical problems continue to predominate among Australian adolescents’ reasons for visit to general practice, psychological presentations occur much more frequently than estimated in past studies. This study also demonstrates that general practice electronic medical records data can be harnessed to provide a meaningful description of primary care activity.
- 14 July 2025
- Published by CSIRO Publishing in Australian Journal of Primary Health
- Vol. 31 (4)
Open AccessAdolescent health presentations to Victorian general practice: a descriptive study using electronic medical records
Background: Although most young Australians visit their general practitioner at least once a year, discrepancies remain between healthcare need and healthcare support in this group. A detailed contemporary understanding of youth presentations to general practice is needed, given that the last comprehensive investigation into Australian adolescent encounters with primary care is now over two decades old. The aim of this study is to describe rates of presentation and reasons for visit among young people in Victorian primary care using data extracted from electronic medical records. Methods: A retrospective descriptive study of de-identified electronic medical records data from >22,000 adolescents aged 10–24 years who presented to Victorian general practice in 2019 was undertaken. Results: The overall mean attendance rate of young people was 2.89 visits/patient per year, with rates highest amongst older patients, females and those in regional localities. Young people presented most frequently for physical (biomedical) concerns (such as respiratory, skin and general physical complaints), and psychological (mental health) reasons for visit. Conclusions: The study addresses a significant gap in our understanding of the role of general practice for young Australians. Although physical problems continue to predominate among Australian adolescents’ reasons for visit to general practice, psychological presentations occur much more frequently than estimated in past studies. This study also demonstrates that general practice electronic medical records data can be harnessed to provide a meaningful description of primary care activity.
- Open Access
- 3 February 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e54147
Effectiveness of Electronic Quality Improvement Activities to Reduce Cardiovascular Disease Risk in People With Chronic Kidney Disease in General Practice: Cluster Randomized Trial With Active Control
Background: Future Health Today (FHT) is a program integrated with electronic medical record (EMR) systems in general practice and comprises (1) a practice dashboard to identify people at risk of, or with, chronic disease who may benefit from intervention; (2) active clinical decision support (CDS) at the point of care; and (3) quality improvement activities. One module within FHT aims to facilitate cardiovascular disease (CVD) risk reduction in people with chronic kidney disease (CKD) through the recommendation of angiotensin-converting enzyme inhibitor inhibitors (ACEI), angiotensin receptor blockers (ARB), or statins according to Australian guidelines (defined as appropriate pharmacological therapy). Objective: This study aimed to determine if the FHT program increases the proportion of general practice patients with CKD receiving appropriate pharmacological therapy (statins alone, ACEI or ARB alone, or both) to reduce CVD risk at 12 months postrandomization compared with active control (primary outcome). Methods: General practices recruited through practice-based research networks in Victoria and Tasmania were randomly allocated 1:1 to the FHT CKD module or active control. The intervention was delivered to practices between October 4, 2021, and September 30, 2022. Data extracted from EMRs for eligible patients identified at baseline were used to evaluate the trial outcomes at the completion of the intervention period. The primary analysis used an intention-to-treat approach. The intervention effect for the primary outcome was estimated with a marginal logistic model using generalized estimating equations with robust SE. Results: Overall, of the 734 eligible patients from 19 intervention practices and 715 from 21 control practices, 82 (11.2%) and 70 (9.8%), respectively, had received appropriate pharmacological therapy (statins alone, ACEI or ARB alone, or both) at 12 months postintervention to reduce CVD risk, with an estimated between-trial group difference (Diff) of 2.0% (95% CI –1.6% to 5.7%) and odds ratio of 1.24 (95% CI 0.85 to 1.81; P=.26). Of the 470 intervention patients and 425 control patients that received a recommendation for statins, 61 (13%) and 38 (9%) were prescribed statins at follow-up (Diff 4.3%, 95% CI 0 to 8.6%; odds ratio 1.55, 95% CI 1.02 to 2.35; P=.04). There was no statistical evidence to support between-group differences in other secondary outcomes and general practice health care use. Conclusions: FHT harnesses the data stored within EMRs to translate guidelines into practice through quality improvement activities and active clinical decision support. In this instance, it did not result in a difference in prescribing or clinical outcomes except for small changes in statin prescribing. This may relate to COVID-19–related disruptions, technical implementation challenges, and recruiting higher performing practices to the trial. A separate process evaluation will further explore factors impacting implementation and engagement with FHT. Trial Registration: ACTRN12620000993998; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380119
- 3 February 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e54147
Open AccessEffectiveness of Electronic Quality Improvement Activities to Reduce Cardiovascular Disease Risk in People With Chronic Kidney Disease in General Practice: Cluster Randomized Trial With Active Control
Background: Future Health Today (FHT) is a program integrated with electronic medical record (EMR) systems in general practice and comprises (1) a practice dashboard to identify people at risk of, or with, chronic disease who may benefit from intervention; (2) active clinical decision support (CDS) at the point of care; and (3) quality improvement activities. One module within FHT aims to facilitate cardiovascular disease (CVD) risk reduction in people with chronic kidney disease (CKD) through the recommendation of angiotensin-converting enzyme inhibitor inhibitors (ACEI), angiotensin receptor blockers (ARB), or statins according to Australian guidelines (defined as appropriate pharmacological therapy). Objective: This study aimed to determine if the FHT program increases the proportion of general practice patients with CKD receiving appropriate pharmacological therapy (statins alone, ACEI or ARB alone, or both) to reduce CVD risk at 12 months postrandomization compared with active control (primary outcome). Methods: General practices recruited through practice-based research networks in Victoria and Tasmania were randomly allocated 1:1 to the FHT CKD module or active control. The intervention was delivered to practices between October 4, 2021, and September 30, 2022. Data extracted from EMRs for eligible patients identified at baseline were used to evaluate the trial outcomes at the completion of the intervention period. The primary analysis used an intention-to-treat approach. The intervention effect for the primary outcome was estimated with a marginal logistic model using generalized estimating equations with robust SE. Results: Overall, of the 734 eligible patients from 19 intervention practices and 715 from 21 control practices, 82 (11.2%) and 70 (9.8%), respectively, had received appropriate pharmacological therapy (statins alone, ACEI or ARB alone, or both) at 12 months postintervention to reduce CVD risk, with an estimated between-trial group difference (Diff) of 2.0% (95% CI –1.6% to 5.7%) and odds ratio of 1.24 (95% CI 0.85 to 1.81; P=.26). Of the 470 intervention patients and 425 control patients that received a recommendation for statins, 61 (13%) and 38 (9%) were prescribed statins at follow-up (Diff 4.3%, 95% CI 0 to 8.6%; odds ratio 1.55, 95% CI 1.02 to 2.35; P=.04). There was no statistical evidence to support between-group differences in other secondary outcomes and general practice health care use. Conclusions: FHT harnesses the data stored within EMRs to translate guidelines into practice through quality improvement activities and active clinical decision support. In this instance, it did not result in a difference in prescribing or clinical outcomes except for small changes in statin prescribing. This may relate to COVID-19–related disruptions, technical implementation challenges, and recruiting higher performing practices to the trial. A separate process evaluation will further explore factors impacting implementation and engagement with FHT. Trial Registration: ACTRN12620000993998; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380119
- Open Access
- 20 November 2024
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 75 (754) , e306-e315
Future Health Today and patients at risk of undiagnosed cancer: a pragmatic cluster randomised trial of quality- improvement activities in general practice
Background: Diagnosing cancer in general practice is complex, given the non-specific nature of many presenting symptoms and the overlap of potential diagnoses. Aim: This trial aimed to evaluate the effectiveness of Future Health Today (FHT) — a technology that provides clinical decision support, auditing, and quality-improvement monitoring — on the appropriate follow-up of patients at risk of undiagnosed cancer. Design and setting: Pragmatic, cluster randomised trial undertaken in general practices in Victoria and Tasmania, Australia. Method: Practices were randomly assigned to receive recommendations for follow-up investigations for cancer (FHT cancer module) or the active control. Algorithms were applied to the electronic medical record, and used demographic information and abnormal test results that are associated with a risk of undiagnosed cancer (that is, anaemia/iron deficiency, thrombocytosis, and raised prostate-specific antigen) to identify patients requiring further investigation and provide recommendations for care. The intervention consisted of the FHT cancer module, a case-based learning series, and ongoing practice support. Using the intention-to-treat approach, the between-arm difference in the proportion of patients with abnormal test results who were followed up according to guidelines was determined at 12 months. Results: In total, 7555 patients were identified as at risk of undiagnosed cancer. At 12 months post-randomisation, 76.0% of patients in the intervention arm had received recommended follow-up (21 practices, n = 2820/3709), compared with 70.0% in the control arm (19 practices, n = 2693/3846; estimated between-arm difference = 2.6% [95% confidence interval (CI)] = −2.8% to 7.9%; odds ratio = 1.15 [95% CI = 0.87 to 1.53]; P = 0.332). Conclusion: The FHT cancer module intervention did not increase the proportion of patients receiving guideline-concordant care. The proportion of patients receiving recommended follow-up was high, suggesting a possible ceiling effect for the intervention.
- 20 November 2024
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 75 (754) , e306-e315
Open AccessFuture Health Today and patients at risk of undiagnosed cancer: a pragmatic cluster randomised trial of quality- improvement activities in general practice
Background: Diagnosing cancer in general practice is complex, given the non-specific nature of many presenting symptoms and the overlap of potential diagnoses. Aim: This trial aimed to evaluate the effectiveness of Future Health Today (FHT) — a technology that provides clinical decision support, auditing, and quality-improvement monitoring — on the appropriate follow-up of patients at risk of undiagnosed cancer. Design and setting: Pragmatic, cluster randomised trial undertaken in general practices in Victoria and Tasmania, Australia. Method: Practices were randomly assigned to receive recommendations for follow-up investigations for cancer (FHT cancer module) or the active control. Algorithms were applied to the electronic medical record, and used demographic information and abnormal test results that are associated with a risk of undiagnosed cancer (that is, anaemia/iron deficiency, thrombocytosis, and raised prostate-specific antigen) to identify patients requiring further investigation and provide recommendations for care. The intervention consisted of the FHT cancer module, a case-based learning series, and ongoing practice support. Using the intention-to-treat approach, the between-arm difference in the proportion of patients with abnormal test results who were followed up according to guidelines was determined at 12 months. Results: In total, 7555 patients were identified as at risk of undiagnosed cancer. At 12 months post-randomisation, 76.0% of patients in the intervention arm had received recommended follow-up (21 practices, n = 2820/3709), compared with 70.0% in the control arm (19 practices, n = 2693/3846; estimated between-arm difference = 2.6% [95% confidence interval (CI)] = −2.8% to 7.9%; odds ratio = 1.15 [95% CI = 0.87 to 1.53]; P = 0.332). Conclusion: The FHT cancer module intervention did not increase the proportion of patients receiving guideline-concordant care. The proportion of patients receiving recommended follow-up was high, suggesting a possible ceiling effect for the intervention.
- Open Access
- 7 November 2023
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 131 (4) , 508-517
Global impacts of COVID‐19 pandemic on sexual and reproductive health services: An international comparative study on primary care from the INTRePID Consortium
Objective: To understand how the COVID‐19 pandemic has impacted sexual and reproductive health (SRH) visits.Design: An ecological study comparing SRH services volume in different countries before and after the onset of the COVID‐19 pandemic.Setting: Seven countries from theINTernational ConsoRtium ofPrimary Care BIgData Researchers (INTRePID) across four continents.Population: Over 3.8 million SRH visits to primary care physicians in Australia, China, Canada, Norway, Singapore, Sweden and the USA.Methods: Difference in average SRH monthly visits before and during the pandemic, with negative binomial regression modelling to compare predicted and observed number of visits during the pandemic for SRH visits.Main outcome measures: Monthly number of visits to primary care physicians from 2018 to 2021.Results: During the pandemic, the average volume of monthly SRH visits increased in Canada (15.6%, 99% CI 8.1–23.0%) where virtual care was pronounced. China, Singapore, Sweden and the USA experienced a decline (−56.5%, 99% CI −74.5 to −38.5%; −22.7%, 99% CI −38.8 to −6.5%; −19.4%, 99% CI −28.3 to −10.6%; and −22.7%, 99% CI −38.8 to −6.5%, respectively); while Australia and Norway showed insignificant changes (6.5%, 99% CI −0.7 to –13.8% and 1.7%, 99% CI −6.4 to –9.8%). The countries that maintained (Australia, Norway) or surpassed (Canada) pre‐pandemic visit rates had the greatest use of virtual care.Conclusions: In‐person SRH visits to primary care decreased during the pandemic. Virtual care seemed to counterbalance that decline. Although cervical cancer screening appeared insensitive to virtual care, strategies such as incorporating self‐collected samples for HPV testing may provide a solution in a future pandemic.
- 7 November 2023
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 131 (4) , 508-517
Open AccessGlobal impacts of COVID‐19 pandemic on sexual and reproductive health services: An international comparative study on primary care from the INTRePID Consortium
Objective: To understand how the COVID‐19 pandemic has impacted sexual and reproductive health (SRH) visits.Design: An ecological study comparing SRH services volume in different countries before and after the onset of the COVID‐19 pandemic.Setting: Seven countries from theINTernational ConsoRtium ofPrimary Care BIgData Researchers (INTRePID) across four continents.Population: Over 3.8 million SRH visits to primary care physicians in Australia, China, Canada, Norway, Singapore, Sweden and the USA.Methods: Difference in average SRH monthly visits before and during the pandemic, with negative binomial regression modelling to compare predicted and observed number of visits during the pandemic for SRH visits.Main outcome measures: Monthly number of visits to primary care physicians from 2018 to 2021.Results: During the pandemic, the average volume of monthly SRH visits increased in Canada (15.6%, 99% CI 8.1–23.0%) where virtual care was pronounced. China, Singapore, Sweden and the USA experienced a decline (−56.5%, 99% CI −74.5 to −38.5%; −22.7%, 99% CI −38.8 to −6.5%; −19.4%, 99% CI −28.3 to −10.6%; and −22.7%, 99% CI −38.8 to −6.5%, respectively); while Australia and Norway showed insignificant changes (6.5%, 99% CI −0.7 to –13.8% and 1.7%, 99% CI −6.4 to –9.8%). The countries that maintained (Australia, Norway) or surpassed (Canada) pre‐pandemic visit rates had the greatest use of virtual care.Conclusions: In‐person SRH visits to primary care decreased during the pandemic. Virtual care seemed to counterbalance that decline. Although cervical cancer screening appeared insensitive to virtual care, strategies such as incorporating self‐collected samples for HPV testing may provide a solution in a future pandemic.
- Open Access
- 31 October 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Effectiveness of Electronic Quality Improvement Activities to Reduce Cardiovascular Disease Risk in People With Chronic Kidney Disease in General Practice: Cluster Randomized Trial With Active Control (Preprint)
BACKGROUND Future Health Today (FHT) is a program integrated with electronic medical record (EMR) systems in general practice and comprises (1) a practice dashboard to identify people at risk of, or with, chronic disease who may benefit from intervention; (2) active clinical decision support (CDS) at the point of care; and (3) quality improvement activities. One module within FHT aims to facilitate cardiovascular disease (CVD) risk reduction in people with chronic kidney disease (CKD) through the recommendation of angiotensin-converting enzyme inhibitor inhibitors (ACEI), angiotensin receptor blockers (ARB), or statins according to Australian guidelines (defined as appropriate pharmacological therapy). OBJECTIVE This study aimed to determine if the FHT program increases the proportion of general practice patients with CKD receiving appropriate pharmacological therapy (statins alone, ACEI or ARB alone, or both) to reduce CVD risk at 12 months postrandomization compared with active control (primary outcome). METHODS General practices recruited through practice-based research networks in Victoria and Tasmania were randomly allocated 1:1 to the FHT CKD module or active control. The intervention was delivered to practices between October 4, 2021, and September 30, 2022. Data extracted from EMRs for eligible patients identified at baseline were used to evaluate the trial outcomes at the completion of the intervention period. The primary analysis used an intention-to-treat approach. The intervention effect for the primary outcome was estimated with a marginal logistic model using generalized estimating equations with robust SE. RESULTS Overall, of the 734 eligible patients from 19 intervention practices and 715 from 21 control practices, 82 (11.2%) and 70 (9.8%), respectively, had received appropriate pharmacological therapy (statins alone, ACEI or ARB alone, or both) at 12 months postintervention to reduce CVD risk, with an estimated between-trial group difference (Diff) of 2.0% (95% CI –1.6% to 5.7%) and odds ratio of 1.24 (95% CI 0.85 to 1.81; P=.26). Of the 470 intervention patients and 425 control patients that received a recommendation for statins, 61 (13%) and 38 (9%) were prescribed statins at follow-up (Diff 4.3%, 95% CI 0 to 8.6%; odds ratio 1.55, 95% CI 1.02 to 2.35; P=.04). There was no statistical evidence to support between-group differences in other secondary outcomes and general practice health care use. CONCLUSIONS FHT harnesses the data stored within EMRs to translate guidelines into practice through quality improvement activities and active clinical decision support. In this instance, it did not result in a difference in prescribing or clinical outcomes except for small changes in statin prescribing. This may relate to COVID-19–related disruptions, technical implementation challenges, and recruiting higher performing practices to the trial. A separate process evaluation will further explore factors impacting implementation and engagement with FHT. CLINICALTRIAL ACTRN12620000993998; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380119
- 31 October 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEffectiveness of Electronic Quality Improvement Activities to Reduce Cardiovascular Disease Risk in People With Chronic Kidney Disease in General Practice: Cluster Randomized Trial With Active Control (Preprint)
BACKGROUND Future Health Today (FHT) is a program integrated with electronic medical record (EMR) systems in general practice and comprises (1) a practice dashboard to identify people at risk of, or with, chronic disease who may benefit from intervention; (2) active clinical decision support (CDS) at the point of care; and (3) quality improvement activities. One module within FHT aims to facilitate cardiovascular disease (CVD) risk reduction in people with chronic kidney disease (CKD) through the recommendation of angiotensin-converting enzyme inhibitor inhibitors (ACEI), angiotensin receptor blockers (ARB), or statins according to Australian guidelines (defined as appropriate pharmacological therapy). OBJECTIVE This study aimed to determine if the FHT program increases the proportion of general practice patients with CKD receiving appropriate pharmacological therapy (statins alone, ACEI or ARB alone, or both) to reduce CVD risk at 12 months postrandomization compared with active control (primary outcome). METHODS General practices recruited through practice-based research networks in Victoria and Tasmania were randomly allocated 1:1 to the FHT CKD module or active control. The intervention was delivered to practices between October 4, 2021, and September 30, 2022. Data extracted from EMRs for eligible patients identified at baseline were used to evaluate the trial outcomes at the completion of the intervention period. The primary analysis used an intention-to-treat approach. The intervention effect for the primary outcome was estimated with a marginal logistic model using generalized estimating equations with robust SE. RESULTS Overall, of the 734 eligible patients from 19 intervention practices and 715 from 21 control practices, 82 (11.2%) and 70 (9.8%), respectively, had received appropriate pharmacological therapy (statins alone, ACEI or ARB alone, or both) at 12 months postintervention to reduce CVD risk, with an estimated between-trial group difference (Diff) of 2.0% (95% CI –1.6% to 5.7%) and odds ratio of 1.24 (95% CI 0.85 to 1.81; P=.26). Of the 470 intervention patients and 425 control patients that received a recommendation for statins, 61 (13%) and 38 (9%) were prescribed statins at follow-up (Diff 4.3%, 95% CI 0 to 8.6%; odds ratio 1.55, 95% CI 1.02 to 2.35; P=.04). There was no statistical evidence to support between-group differences in other secondary outcomes and general practice health care use. CONCLUSIONS FHT harnesses the data stored within EMRs to translate guidelines into practice through quality improvement activities and active clinical decision support. In this instance, it did not result in a difference in prescribing or clinical outcomes except for small changes in statin prescribing. This may relate to COVID-19–related disruptions, technical implementation challenges, and recruiting higher performing practices to the trial. A separate process evaluation will further explore factors impacting implementation and engagement with FHT. CLINICALTRIAL ACTRN12620000993998; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380119